Benralizumab for the prevention of COPD exacerbations
<p><h4>BACKGROUND</h4></p> <p>The efficacy and safety of benralizumab, an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are n...
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
Massachusetts Medical Society
2019
|